25 May 2013
Keywords: gsk, defends, avandia, against, findings, cv, risk
Article | 17 December 2007
Concerns about the cardiovascular safety of glitazone drugs were raised once again with the publication of the first population-based study ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 December 2007
24 December 2007
24 May 2013
© 2013 thepharmaletter.com